INSM Form 4: William Lewis Exercises 6,865 Options and Executes 10b5-1 Sales
Rhea-AI Filing Summary
Insmed Inc. insider transactions by Chair and CEO William Lewis show option exercises and multiple stock sales executed under a 10b5-1 plan on 08/18/2025. The filing reports the exercise of 6,865 stock options at an exercise price of $10.85 and the acquisition of 6,865 common shares via that exercise. On the same date the reporting person sold a total of 6,865 common shares in separate sell transactions: 2,968 shares at a weighted average price of $127.59, 2,481 shares at $128.76, and 1,416 shares at $129.47. After these transactions the reporting person beneficially owns 303,911 shares indirectly and 50,500 shares indirectly via two trusts.
Positive
- Transactions executed under a documented 10b5-1 plan, indicating pre-planned and rule-compliant insider sales.
- Options exercised at $10.85 converting to 6,865 shares, illustrating intrinsic value capture versus exercise price.
Negative
- Insider sold 6,865 shares on 08/18/2025, reducing holdings via three sell blocks (2,968; 2,481; 1,416 shares).
- Reported sales at high market prices may be perceived as insider monetization rather than vote of confidence in near-term upside.
Insights
TL;DR: Option exercise followed by plan-led share sales is routine insider liquidity, disclosed under a pre-existing 10b5-1 plan.
The Form 4 indicates the reporting person adopted a 10b5-1 trading plan on September 12, 2024, and executed transactions on August 18, 2025 pursuant to that plan. The disclosure shows option exercises converting to 6,865 shares and contemporaneous open-market sales of the same aggregate amount across three sale blocks at weighted average prices between $127.59 and $129.47. The filing includes clear pricing ranges and an undertaking to provide per-price breakdowns on request, which supports compliance and transparency. Impact is procedural rather than operational.
TL;DR: Insider monetized equity via exercised options and market sales; remaining indirect holdings remain sizeable.
The report shows an exercise price of $10.85 for 6,865 options that became exercisable and were exercised on 08/18/2025. Proceeds were partially realized by selling those shares in three blocks totaling 6,865 shares at weighted average sale prices of $127.59, $128.76, and $129.47. Post-transactions beneficial ownership is reported as 303,911 shares (indirect) plus 50,500 shares (indirect by another trust). For investors, this is a liquidity event by an insider rather than new information about company performance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,865 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,865 | $10.85 | $74K |
| Sale | Common Stock | 2,968 | $127.59 | $379K |
| Sale | Common Stock | 2,481 | $128.76 | $319K |
| Sale | Common Stock | 1,416 | $129.47 | $183K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (5)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. This is the weighted average sales price representing 2,968 shares sold at prices ranging from $127.20 to $128.16 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3. This is the weighted average sales price representing 2,481 shares sold at prices ranging from $128.26 to $129.21 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4. This is the weighted average sales price representing 1,416 shares sold at prices ranging from $129.26 to $129.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F5. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
